Press release
OX-40 Receptor Agonist Therapeutics Pipeline Analysis - Clinical Trials & Results, Patent, Collaboration, and Other Developments
The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline
According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample
Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline
In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.
OX-40 Receptor Agonist Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OX-40 Receptor Agonist Therapeutics Pipeline Analysis - Clinical Trials & Results, Patent, Collaboration, and Other Developments here
News-ID: 865499 • Views: …
More Releases from P&S Market Research

Smart Cities Market Size, Revenue, Technology, Competitive Analysis, Growth Driv …
The global smart cities market is growing at a CAGR above 20% during 2018 - 2023 and will reach $2578.0 billion by 2023. Due to significant growth in automation technologies such as internet of things (IoT) and adoption of cloud based technologies, the global smart cities market is gaining huge traction. In addition, effective city asset management for public welfare, substantial operational cost savings, and automated public data generation applications…

Global Sports Food Market Expected to Witness 9.2% CAGR During 2016 – 2022
The global sports food market is expected to grow at a CAGR of 9.2% in terms of value during 2016 - 2022. Among the various types, the energy bars segment accounted for the largest share (71.5%) in the global sports food market in 2015.
Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-food-market/report-sample
The manufacturers are trying to bring about products with the best blend of taste and healthy ingredients. They have started to…

Sports Nutrition Market by Type, Distribution Channel, Region, Growth and Demand …
The global sports nutrition market is expected to grow at a CAGR of 8.4% in terms of value during 2016 - 2022. Among the various types, the sports drinks segment accounted for largest share (61.4%) in the global sports nutrition market in 2015.
Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-nutrition-market/report-sample
The increasing health concerns, such as obesity and awareness of physical appearances among all consumers groups is driving the demand for sports…

Orthopedic Trauma Devices Market Supply Chain Trends Mapping the Latest Technolo …
The global orthopedic trauma devices market is growing due to the increasing frequency of fractures, along with the growth of aging population. The advantageous features posed by orthopedic trauma devices, such as internal and external fixators to set a fracture, and in repositioning of bone fragments into their normal alignment are also driving the growth of the market worldwide. Furthermore, the internal fixators have reduced the hospital stays, reduced the…
More Releases for Receptor
Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market: Competitive Dyna …
Global Info Research offers a latest published report on Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in…
DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologo …
DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Pipeline Insight, 2020 report by comprehensive insights of present scenario and growth prospects across DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action,…
TRAIL Receptor 1 & Receptor 2 Agonist Pipeline Analysis 2020 Along with Research …
TRAIL Receptor 1 & Receptor 2 Agonist -Pipeline Insight, 2020: The report presents an in-depth assessment of TRAIL Receptor 1 & Receptor 2 Agonist including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for TRAIL Receptor 1 & Receptor 2 Agonist investments from 2020 till 2030
Major Key Players:AbbVie,…
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Recept …
Market Research Hub (MRH) has added a new report titled “Calcitonin Gene Related Peptide Type 1 Receptor, Pharmaceutical Pipeline Research Report” to its vast data repository. Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1…
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Rece …
"Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global Markets Directs, Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016, provides in depth analysis on Transient Receptor Potential Cation…
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Recepto …
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016, provides in depth analysis on Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted pipeline therapeutics.
The report provides comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1), targeted therapeutics, complete with analysis by…